CAMBRIDGE, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- —KRRO-110 produced functional protein in Alpha-1 Antitrypsin Deficiency (AATD) patients —KRRO-110 did not reach projected levels of functional protein following a single administration —Pivoting to GalNAc delivery for patients with AATD; development candidate nomination expected in the first half of 2026 —Nominated KRRO-121, designed to create a de novo protein variant to activate a biological pathway for patients with hyperammonemia —Reports third qu ...